Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02918266 · ClinicalTrials.gov registry record · Phase 1
TAK-071 Scopolamine-Induced Cognitive Impairment Study
A Phase 1 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT02918266: Clinical Trial Phase 1 study, sponsored by Takeda.
NCT02918266 is a Phase 1 study that was terminated before completion, run by Takeda. The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02918266, a Phase 1 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effect of a single oral dose of TAK-071 on the attenuation of cognitive deficit induced by scopolamine as measured by Groton Maze Learning Test (GMLT) (total number of errors).
Interventions
- DRUG Donepezil
- DRUG Scopolamine
- DRUG TAK-071
- DRUG TAK-071 Placebo
- DRUG Scopolamine Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-11-21 |
| Est. Completion | 2017-08-08 |
| Phase | Phase 1 |
Why NCT02918266 stopped before completion
NCT02918266 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 5 interventions - of which Donepezil is the first listed.
NCT02918266 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02918266 about?
NCT02918266 is a clinical study titled "TAK-071 Scopolamine-Induced Cognitive Impairment Study". The purpose of this study is to assess the effect of a single oral dose of TAK-071 on the attenuation of cognitive deficit induced by scopolamine as measured by Groton Maze Learning Test (GMLT) (total number of errors).
What is the current status of trial NCT02918266?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2016-11-21. Estimated completion is 2017-08-08.
What interventions are being tested in trial NCT02918266?
The interventions under investigation include: Donepezil (DRUG), Scopolamine (DRUG), TAK-071 (DRUG), TAK-071 Placebo (DRUG), Scopolamine Placebo (DRUG).
Who is sponsoring clinical trial NCT02918266?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02918266's enrollment target sits among peer trials
18 1720th of 2000 higher than 216 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI